Pancreatic cancer is affecting individuals and their families worldwide. According to recent statistics from the World Health Organization (WHO) , pancreatic cancer remains one of the most challenging forms of cancer, with a high mortality rate. Amidst this grim reality, there is a glimmer of hope in the form of innovative therapies such as Dendritic Cell Therapy (DCT). This article delves into the statistics of pancreatic cancer at Immucura, examining the distribution of cases by grade, the presence of metastases, and the efficacy of DCT in improving survival rates for pancreatic cancer patients.
Comprehensive research conducted at Immucura between December 2020 and April 2023 involved the analysis of cancer statistics and survival rates for 12 pancreatic cancer patients. This research not only yields critical insights into the prevalence and outcomes of pancreatic cancer but also delves into the distribution of cases by grade, assesses the presence of metastases, and presents the survival rates for patients diagnosed with this challenging form of cancer.
In addition to the analysis of pancreatic cancer, an examination of Immucura’s global patient data (total number = 409) reveals a nearly equal distribution between sexes, with 49.6% male and 50.4% female patients. Among the 24 cancer types recorded, a sample of 117 patients was selected for a study. Notably, pancreatic cancer accounted for 10.3% of cases, underscoring the importance of addressing this relatively prevalent cancer type alongside other noteworthy types such as breast cancer (22.2%), brain and central nervous system cancers (12.8%), colorectal cancer (11.1%), and prostate cancer (7.7%). These findings collectively emphasize the significance of understanding and addressing pancreatic cancer.
Among the 12 pancreatic cancer patients monitored , grade 4 pancreatic cancer stands out as the dominant grade, representing a staggering 91.7% of cases. Conversely, the percentage of patients with unknown-grade pancreatic cancer is 8.3%. These statistics underscore the severity and advanced stage of pancreatic cancer cases typically seen at Immucura.
When considering metastases in pancreatic cancer, the data reveals that this disease often presents at an advanced stage. The majority of patients 91.7% had metastatic pancreatic cancer, emphasizing the urgency of effective therapies for advanced-stage diseases.
Survival rates are a critical measure of the effectiveness of any cancer therapy. In the case of pancreatic cancer, Immucura’s data highlights the challenging nature of this disease. After one year of diagnosis, the survival rate among pancreatic cancer patients at Immucura is 41.7%, based on the 12 patients analyzed. This percentage underscores the need for improved therapy options and early detection methods for pancreatic cancer.
In conclusion, pancreatic cancer poses a significant challenge in the field of oncology, with the majority of patients at Immucura presenting with grade 4 pancreatic cancer and metastatic disease. The data highlights the severity and advanced stage of pancreatic cancer cases typically seen at Immucura. Furthermore, the one-year survival rate for pancreatic cancer patients at Immucura is 41.7%, reflecting the urgent need for more effective therapies for this devastating disease.